Arthritis Pain is an indication for drug development with over 80 pipeline drugs currently active. According to GlobalData, preregistered drugs for Arthritis Pain have a 72.73% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Arthritis Pain compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Arthritis Pain overview
Arthritis pain stems from inflammation in joints, causing discomfort, swelling, stiffness, and reduced mobility. Osteoarthritis, the most common type, occurs due to wear and tear on joint cartilage, while rheumatoid arthritis involves the immune system attacking joints. Symptoms worsen over time, impacting daily life and often leading to chronic pain. Treatments focus on pain management, preserving joint function, and reducing inflammation, employing medications, physical therapy, lifestyle adjustments, and in severe cases, surgery. Personalized care aims to alleviate pain, improve mobility, and enhance the individual’s quality of life despite the challenges posed by arthritis..
See Also:
For a complete picture of PTSR and LoA scores for drugs in Arthritis Pain, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
